A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 877-884

  Gazitt, Yair ^a   Shaughnessy, Paul ^b   Rothenberg, Mace L ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TEXAS TRANSPLANT INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Multiple myeloma; Paclitaxel; Phase II

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

AGED; APOPTOSIS; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PACLITAXEL; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049185107     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.877     Document Type: Article

References (46)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Barlogie B, Epstein J, Selvanayagam P and Alexanian R: Plasma cell myeloma-new biological insights and advances in therapy. Blood 73: 865-879, 1989. (Pubitemid 19078360)
3. Abdou NI and Abdou NL: The monoclonal nature of lymphocytes in multiple myeloma. Ann Intern Med 83: 42-45, 1975.
4. Gregory W, Richards M and Malpas J: Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 336-342, 1992.
5. Attal M, Harousseau J-L, Stoppa A-M, et al : A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97, 1996. (Pubitemid 26240110)
6. Barlogie B, Hall R, Zander A, Dicke K and Alexanian R: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67: 1298-1301, 1986. (Pubitemid 16080597)
7. Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Foumie B, Mazieres B, Pris J and Laurent G: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79: 1130-1136, 1992.
8. Child J, Morgan G, Davies F, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883, 2003. (Pubitemid 36532313)
9. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R and Crowley J: Treatment of multiple myeloma. Blood 103: 20-32, 2004. (Pubitemid 38029914)
10. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindel S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Hoffman R and Barlogie B: Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 91: 4489-4495, 1998. (Pubitemid 28270295)
11. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC and Berenson J: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19: 3771-3779, 2001. (Pubitemid 32844791)
12. Singhal S, Mehta J, Desikan R, et al : Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
13. Barlogie B, Tricot G and Anaissie E: Thalidomide in the management of multiple myeloma. Semin Oncol 28: 577-582, 2002.
14. Kumar S, Gertz MA, Dispenzieri A, et al : Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34-39, 2003. (Pubitemid 36033958)
15. Richardson PG, Schlossman RL, Weller E, et al : Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067, 2002. (Pubitemid 35217050)
16. Richardson PG, Hideshima T, Mitsiades C and Anderson K: Proteasome inhibition in hematologic malignancies. Ann Med 36: 304-314, 2004. (Pubitemid 38789285)
17. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990. (Pubitemid 20225688)
18. Waud WR, Gilbert KS, Grindey GB and Worzalla JF: Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias. Cancer Chemother Pharmacol 38: 178-180, 1996. (Pubitemid 26132406)
19. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self potentiation. Cancer Res 52: 533-539, 1992.
20. Ruiz von Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB and Peters GJ: Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solide tumour cell lines and solid tumours. Biochem Pharmacol 48: 1327-1339, 1994.
21. Heinemann V, Hertel L W, Grindey GB and Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxyctidine and I-beta- D-arabinofuranosyl cytosine. Cancer Res 48: 4024-4031, 1988.
22. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG and Von Hoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A: 417-418, 1994. (Pubitemid 24152493)
23. Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M and Baker L: Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs 10: 165-170, 1992.
24. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN and Plunkett W: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991.
25. Vermorken JB, Guastalla JP, Hatty SR, Seitz DE, Tanis B, McDaniels C and Clavel MD: Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer 76: 1489-1493, 1997. (Pubitemid 27501133)
26. Brand R, Capadano M and Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15: 331-341, 1997. (Pubitemid 28098500)
27. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990. (Pubitemid 20239995)
28. Rothenberg ML: Taxol, Taxotere and other new taxanes. Curr Opin Invest Drugs 2: 1269-1277, 1993.
29. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
30. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270, 1994. (Pubitemid 24346693)
31. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993. (Pubitemid 23073156)
32. Caldas C and McGuire WP III: Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol 4 (suppl 3): 50-55, 1993. (Pubitemid 23239396)
33. Forastiere AA, Neuberg D, Taylor SG IV, DeConti R and Adams G: Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Natl Cancer Inst Monogr 15: 181-184, 1993.
34. Gazitt Y, Rothenberg ML, Hilsenbeck SL, Fey V, Thomas C and Montgomery W: Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int J Oncol 13: 839-848, 1998. (Pubitemid 28435362)
35. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23 (suppl 1): 37-43, 1996.
36. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA III, Eckhardt SG, Stephens CD, Forral K, Nicol SJ and Von Hoff DD: Phase I trial of paclitaxel and gemcitabine administered every 2-weeks in patients with refractory solid tumors. Ann Oncol 9: 733-738, 1998. (Pubitemid 28394159)
37. Guchelaar H-J, Richel DJ and van Knapen A: Clinical, toxicological, and pharmacological aspects of gemcitabine. Cancer Treat Rev 22: 15-31, 1996. (Pubitemid 26155745)
38. Fleming TR: One sample multiple testing procedure for phase II clinical trial. Biometrics 38: 143-151, 1982.
39. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al : A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2002.
40. Mitsiades N, Mitsiades C, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al : Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99: 14374-14379, 2002. (Pubitemid 35257679)
41. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102: 1115-1123, 1998. (Pubitemid 28435189)
42. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L and Tricot G: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168-1171, 2002. (Pubitemid 34864267)
43. Weber D, Rankin K, Gavino M, Delasalle K and Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16-19, 2003.
44. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F and Barlogie B: Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 98: 775a, 2001. (Pubitemid 33790485)
45. Richardson PG, Sonneveld P, Schuster MW, et al: Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
46. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP and McConkey DJ: The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics 3: 279-290, 2004. (Pubitemid 39193703)